Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Curaleaf Holdings, Inc. is a cannabis company that operates as a vertically integrated provider of consumer cannabis products. The company focuses on cultivating, processing, and distributing both medical and adult-use cannabis through a network of dispensaries and production facilities across multiple U.S. states and international markets. Its portfolio spans branded flower, vape products, edibles, concentrates, and other derivative formats designed for different consumer preferences and therapeutic needs. Curaleaf Holdings, Inc. serves patients, adult consumers, and wholesale partners, combining retail operations with upstream cultivation and manufacturing capabilities to manage product quality and consistency. The company maintains operations in the United States and extends its reach into regions such as Canada, Europe, Australia, and New Zealand, positioning it as a significant player in the global cannabis industry.
$9.22
+$0.87 (+10.42%)
EOD Aug 6, 2026
Operating margin is thin at 2.01%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 5.6% YoY. The question is whether this is cyclical or a structural shift.
Net debt of $738M represents 10.1x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.28B
▼ -5.6% YoY
Net Income (TTM)
-$152M
▼ -21.8% YoY
Op. Margin
1.43%
▲ +0.5pp YoY
ROIC
1.14%
▲ +0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$55M
▲ +13.4% YoY
Op. Cash Flow (TTM)
$120M
▼ -11.8% YoY
Net Debt
$738M
Cash & Equiv.
$89M
3Y CAGR: -0.2%
Continue Research
Curaleaf Holdings (CURLF) trades above a two-stage DCF intrinsic value of about $7.86 per share, so at $9.22 the stock looks overvalued (14.7% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Curaleaf Holdings scores 31/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $7.86 per share for CURLF, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $5.90. At today's $9.22, that puts the stock about 14.7% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Curaleaf Holdings scores 31 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 1.4% operating margin and a 1.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CURLF currently trades above its estimated intrinsic value and scores 31/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.